SEC Form 4 · accession 0001193125-26-401014
Aktis Oncology, Inc. · AKTS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Akos Czibere
Officer — Chief Medical Officer
Period of report
Sep 23, 2026
Accepted (ET)
Sep 24, 2026 · 4:05 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0002035832
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Sep 23, 2026 | M | 12,500 | $4.95 | A | 12,500 | D | |
| Common StockF2 | Sep 23, 2026 | S | 5,099 | $20.1947 | D | 7,401 | D | |
| Common StockF3 | Sep 23, 2026 | S | 7,401 | $21.0307 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F4 | $4.95 | Sep 23, 2026 | M | 12,500 | D | — | Jun 30, 2034 | Common Stock | 12,500 | 208,718 | D |
Explanation of responses
- F1The transactions reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 24, 2026.
- F2The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.6700 to $20.6500, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- F3The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.6700 to $21.5000, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- F425% of the original number of shares subject to the option vested on July 1, 2025, and 1/48th of the original number of shares subject to the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each vesting date, inclusive.